FUJIFILM Diosynth Biotechnologies to manufacture Novavax COVID-19 vaccine candidate
Novavax and FUJIFILM Diosynth Biotechnologies have agreed for FDB to make the bulk drug substance for NVX-CoV2373, the Novavax COVID-19 vaccine candidate.
List view / Grid view
News
FDA orders update of label change for opioid pain medications
The FDA is requiring that labels for opioid pain medicine and medicines to treat opioid use disorder recommend healthcare professionals discuss the availability of naloxone with patients to reduce overdoses.
Study suggests some excipients in common drugs are biologically active
Preliminary research has revealed that some excipients used in common medications may interact with important human enzymes and receptors.
EMA to monitor real world use of COVID-19 treatments and vaccines
The EMA has built up an infrastructure to allow for the monitoring of COVID-19 treatments and vaccines used in clinical practice.
UK MHRA announces two Class 2 medicine recalls
A batch of Nitrofurantoin and all unexpired stock of Desmopressin nasal spray are being recalled in the UK, the MHRA has announced.
Pfizer and BioNTech to supply up to 600 million doses of COVID-19 vaccine to US
An agreement between the US government and Pfizer and BioNTech will have the companies produce an initial 100 million doses of their COVID-19 vaccine candidate, with the potential for 500 million more.
Novel anti-amyloid drug BAN2401 enters Phase III trial in Alzheimer’s patients
BAN2401 will be tested in various stages of Alzheimer’s disease progression to assess if it can slow the progression of cognitive decline.
Plant-based COVID-19 vaccine enters Phase I trials
The vaccine containing a recombinant coronavirus virus-like particles (CoVLP) will be tested in three different doses and with two different adjuvants.
UK’s SARS-CoV-2 vaccine candidate is safe and induces antibody and T cell response
Data released from the Phase I/II trial of the ChAdOx1 COVID-19 vaccine candidate suggests it elicits an immune response with no adverse effects.
Partnership to fight COVID-19 medication counterfeiting and advance blockchain solutions
The alliance between Chronicled and Deloitte intends to enhance security and efficiency in the pharma supply chain by bring to market new blockchain-powered solutions.
COVID-19 vaccine safely induces immune response in Chinese trial
Investigators report CanSino Biologics’ Ad5-nCoV vaccine induced antibody production with mild to moderate side effects in patients.
UK government secures early access to 90 million doses of COVID-19 vaccines
The government has entered partnerships with Pfizer and Valneva to secure doses of several promising COVID-19 vaccines and secured COVID-19 neutralising antibody treatments from AstraZeneca.
Inhaled interferon beta therapy shows promise in COVID-19 trial
SNG001 diminished the risk of COVID-19 patients developing severe symptoms, reduced breathlessness and improved recovery rates.
Johnson & Johnson to start COVID-19 vaccine trials next week
The company will start enrolment to the Ad26.COV2-S vaccine trial next week, it anticipates initial results in September.
![Novartis logo Novartis building in Stein, Switzerland [Credit: Taljat David shutterstock.com]](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/novartis-image-300x278.jpg)
![Novartis logo Novartis building in Stein, Switzerland [Credit: Taljat David shutterstock.com]](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/novartis-image-scaled-e1594985022657.jpg)
Novartis launches not-for-profit COVID-19 medications portfolio
The portfolio will be offered to low- and lower-middle-income countries to help financially strained healthcare systems care for COVID-19 patients.
